Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4085 | Treatment C Wiki | 1.00 |
| drug4084 | Treatment B Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.27 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Pulmonary obstruction HPO | 0.27 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.26 |
Navigate: Correlations HPO
There is one clinical trial.
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A [test]), Propellant 2 (Treatment B [test]) and Hydrofluoroalkane (HFA) (Treatment C [reference]).
Description: Evaluation of the relative bioavailability between the test formulations and the reference formulation for fixed dose combinations (FDCs) of BGF when delivered as BGF MDI with 3 different propellants by Cmax.
Measure: Maximum observed concentration (Cmax) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Evaluation of the relative bioavailability between the test formulations and the reference formulation for FDCs of BGF when delivered as BGF MDI with 3 different propellants by AUCinf.
Measure: Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Evaluation of the relative bioavailability between the test formulations and the reference formulation for FDCs of BGF when delivered as BGF MDI with 3 different propellants by AUClast.
Measure: Area under the plasma concentration- curve from time zero to the time of last quantifiable concentration (AUClast) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the pharmacokinetic (PK) parameters of BGF when administered as 3 different propellant formulations by tmax.
Measure: Time to reach maximum observed concentration (tmax) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by t½λz.
Measure: Terminal elimination half-life (t½λz) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by MRT.
Measure: Mean residence time in the systemic circulation extrapolated to infinity (MRT) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by λz.
Measure: Terminal elimination rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by CL/F.
Measure: Apparent total body clearance of drug after extravascular administration (CL/F) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by Vz/F.
Measure: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRCmax.
Measure: Treatment ratio for Cmax derived by dividing the Cmax of the test treatment by the reference treatment (TRCmax) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRAUCinf.
Measure: Treatment ratio for AUCinf, derived by dividing the AUCinf of the test treatment by the reference treatment (TRAUCinf) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRAUClast.
Measure: Treatment ratio for AUClast derived by dividing the AUClast of the test treatment by the reference treatment (TRAUClast) of BGF MDI Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-doseDescription: Assessment of the safety and tolerability of a combination of BGF when administered as single doses in 3 different propellant formulations in healthy participants.
Measure: Number of participants with serious adverse events (SAE) and non-serious adverse events Time: Screening (Only SAE), Days -1, 1, and Day 2 until Follow-up visit (approximately 3 to 7 days post final dose)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports